Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · May 31, 2023

Dalpiciclib Plus Letrozole or Anastrozole as First-Line Treatment for HR+/HER2− Advanced Breast Cancer

The Lancet Oncology


Additional Info

Disclosure statements are available on the authors' profiles:

The Lancet Oncology
Dalpiciclib plus letrozole or anastrozole versus placebo plus letrozole or anastrozole as first-line treatment in patients with hormone receptor-positive, HER2-negative advanced breast cancer (DAWNA-2): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
Lancet Oncol 2023 May 11;[EPub Ahead of Print], P Zhang, Q Zhang, Z Tong, T Sun, W Li, Q Ouyang, X Hu, Y Cheng, M Yan, Y Pan, Y Teng, X Yan, Y Wang, W Xie, X Zeng, X Wang, C Hu, C Geng, H Zhang, W Li, X Wu, J Zhong, J Xu, Y Shi, W Wei, N Bayaxi, X Zhu, B Xu

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading